CONNECT WITH US:
May 22, 2017 12:00 JST
Alset International Limited
Singapore eDevelopment Subsidiary Initiates Research on New Universal Drug Platform
- Nobel Prize nominee Daryl Thompson to lead research, conducted by subsidiary Global BioLife Inc., supported by Charles River Laboratories
- Six month target for validating lab data, twelve month target for completion of platform
SINGAPORE, May 22, 2017 - (ACN Newswire) - Singapore eDevelopment Ltd ("SeD") subsidiary Global BioLife Inc. has initiated advanced research on a new universal therapeutic drug platform known as Linebacker, to combat a range of diseases including Alzheimer's, diabetes and cancer. The research will be led by two-time Nobel Prize nominee Mr Daryl Thompson.
SGX-listed SeD (SP:SGE) said Mr Thompson would leverage his expertise in organic and carbohydrate chemistry and the use of pandemic technology in combating the Ebola virus in the development of Linebacker. Unlike traditional approaches to curing individual diseases with specific drugs, the Linebacker platform seeks a breakthrough option for multiple diseases to be cured. It can also potentially combat drug-resistant viruses and antibiotic-resistant bacteria.
Mr Thompson will lead the research, to be conducted by Global BioLife, in his capacity as Director of Scientific Initiatives. Global BioLife is an 80%-held subsidiary of SeD's wholly-owned subsidiary, Global BioMedical Inc. The remaining stake in Global BioLife is held in equal proportions by Mr Thompson's GRDG Sciences LLC and ASX-listed Holista CollTech Limited.
Mr Thompson was nominated for a Nobel Prize in 2015 and 2016 for his research in cutting-edge organic and carbohydrate chemistry as well his research in pandemics technology to fight pandemics such as Ebola. He has used his expertise to initiate research regarding universal therapeutics to cure the world's deadliest diseases. Mr Scott Truesdell, Research Coordinator and Special Projects Leader at Global BioLife, will execute the research on the Linebacker platform.
Global BioLife has engaged NYSE-listed Charles River Laboratories International, Inc., which provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts.
Mr Thompson said, "We expect to obtain validating laboratory data from the universal therapeutic drug platform within the first six months and are targeting for the platform itself to be completed within twelve months. We have a unique patented technology and are already getting interest from Big Pharma players and venture capitalists. This interest will rise as the validating data becomes available."
"Global BioLife recognizes the need for affordable cures to emerging pandemics and we will leverage the team's deep expertise to develop this new universal therapeutic drug platform," said Dr Tang Peihong, Global BioLife Director and CEO. Dr Tang has a Ph.D. in Chemical Engineering and was selected as National Distinguished Expert in China's Thousand Talents Plan in 2012.
GRDG Sciences LLC is a natural products discovery drug research company formed in Florida, USA by Mr Thompson, a natural products scientist. GRDG Sciences works with multiple global institutions such as Charles River. Holista CollTech Ltd is a research-driven biotech company that resulted from the merger of Holista Biotech Sdn Bhd and CollTech Australia Ltd. It is dedicated to delivering first-class natural ingredients and wellness products (www.holista.com).
About Singapore eDevelopment Limited
Incorporated on 9 September 2009, and listed on the Singapore Exchange Catalist (SGX:40V) in July 2010 (SP: SGE; SINE), Singapore eDevelopment is involved in (i) property development and investments primarily in the United States and Western Australia; (ii) Information Technology-related businesses; (iii) development, research, testing, manufacturing, licensing and distribution of biomedical products; and (iv) investment activities. For more information, please visit: www.SeD.com.sg.
Issued on behalf of the Company:
WeR1 Consultants Pte Ltd
Mr Ian Lau
T: +65 6737 4844
Source: Alset International Limited
Sectors: Exchanges & Software, Daily Finance, BioTech, Healthcare & Pharm, Funds & Equities
Copyright ©2020 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
Japanese Research Group Performs Largest Ever Meteorological Calculation on Supercomputer Fugaku
Nov 24, 2020 14:44 JST
Mitsubishi Corporation Signs Contract with Egyptian Government for Phase 1 of Cairo Metro Line 4
Nov 24, 2020 14:15 JST
Fujitsu and LARUS Leverage Power of Graph Database and Graph Explainable AI Technologies to Strengthen Detection of Credit Card Fraud
Nov 24, 2020 10:41 JST
Mitsubishi Heavy Industries Engineering to Establish "Decarbonation Business Department"
Nov 20, 2020 16:53 JST
NEC to Launch PCIe-based Vector Engine Card to Explore New Opportunities in the SME Market
Nov 20, 2020 09:20 JST
Honda to Begin Sales of All-new N-ONE Mini-vehicle
Nov 19, 2020 17:04 JST
Fujitsu, AIST, and RIKEN Achieve Unparalleled Speed on the MLPerf HPC Machine Learning Processing Benchmark Leveraging Leading Japanese Supercomputer Systems
Nov 19, 2020 15:29 JST
NEC Establishes its Global Open RAN Center of Excellence in the U.K. to Accelerate Global Adoption of 5G Open RAN
Nov 19, 2020 15:16 JST
Fujitsu Chosen for the Dow Jones Sustainability World Index for 21st Time
Nov 19, 2020 10:43 JST
Eisai Selected for Membership in Dow Jones Sustainability Asia Pacific Index 2020 for Seventh Time
Nov 18, 2020 20:11 JST
Eisai: Jyseleca (Filgotinib) for Rheumatoid Arthritis Launches in Japan
Nov 18, 2020 20:00 JST
Honda e Becomes First Japanese Vehicle to Win 'German Car of the Year'; Adds to Growing Tally of Global Accolades
Nov 18, 2020 16:32 JST
Japan's Fugaku Retains Title as World's Fastest Supercomputer
Nov 17, 2020 15:45 JST
TOYOTA GAZOO Racing ONE-TWO in Bahrain Secures Drivers' Title
Nov 16, 2020 20:24 JST
MHI Included in Dow Jones Sustainability Asia Pacific Index for Fourth Consecutive Year
Nov 16, 2020 16:59 JST
Fujitsu Launches iCAD SX V8, 3D CAD Processing 3 Million Parts in 0.2 Seconds
Nov 16, 2020 14:38 JST
Eisai Receives Approval for Indication Expansion of Anti-Epileptic Agent Fycompa for Use in Pediatric Patients
Nov 16, 2020 10:06 JST
DENSO Takes a Stake in Envoy, an EV Startup Serving the Commercial Real Estate Industry's Mobility Needs
Nov 13, 2020 19:10 JST
DENSO Invests in Lambda:4 to Enhance Passive Digital Key, Increasing its Positional Accuracy and Security
Nov 13, 2020 18:43 JST
NEC Signs Strategic Collaboration Agreement with AWS -- a first-of-its-kind in Japan
Nov 13, 2020 18:37 JST
More Latest Release >>
Impact BioMedical to Begin Efficacy Testing Pan-Coronavirus Vaccine Under New Wholly Owned Subsidiary Innate Immune, Inc.
October 05 2020 15:25 JST
Impact BioMedical Demonstrates 10-Fold Reduction in Viral Population of COVID-19 in Surface Disinfectant Efficacy Testing of its 3F Antiviral Biofragrance
September 18 2020 17:00 JST
Impact Biomedical initiates Quantum, a new frontier in Pharmaceutical Development
July 31 2020 15:00 JST
Impact Biomedical Achieves COVID-19 Success with Equivir and 3F Biofragrance
June 24 2020 14:00 JST
Impact Biomedical Announces Publication of COVID-19 Research in Peer-Reviewed Journal
June 17 2020 18:00 JST
Impact Biomedical and GRDG Sciences Announce Medical Technology Package Valued at USD 1.39 Billion (SGD 1.97 Billion) by Independent Experts
June 01 2020 13:00 JST
Impact Biomedical's Majority Owned Next Generation Medical Technologies Valued at USD 592 Million (SGD 841 Million) by Independent Experts
April 24 2020 10:00 JST
Impact BioMedical's Linebacker and Equivir inhibit SARS-CoV-2, virus responsible for the COVID-19 outbreak
March 18 2020 11:00 JST
Global BioLife to Present 3F Antimicrobial Fragrance at 2020 ASM Biothreats
November 15 2019 02:00 JST
Global BioLife to present Functional Fragrance Formula at the American Society for Microbiology's Biothreats Conference as a New Method to Prevent and Treat Tuberculosis
October 29 2019 09:00 JST
More Press release >>